Stoke Therapeutics (STOK) Projected to Announce Earnings on Thursday

Key Points

• Stoke Therapeutics is expected to report Q3 2026 results on October 29 after market close, with analysts forecasting a loss of $0.9291 per share and revenue of $8.21 million.
• The company previously missed EPS expectations, reporting a $0.93 loss versus the $0.80 consensus, despite revenue of $9.32 million exceeding estimates. Shares recently traded at $25.04, down 2.6%.
• Analyst sentiment remains broadly positive, with 10 Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $44.25 price target, while insiders have sold $1.07 million of stock over the past 90 days.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) will likely be announcing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Stoke Therapeutics to post earnings of ($0.9291) per share and revenue of $8.21 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The firm had revenue of $9.32 million during the quarter, compared to analysts' expectations of $4.89 million. On average, analysts expect Stoke Therapeutics to post ($3.52) EPS for the current fiscal year and ($3.44) EPS for the next fiscal year.

Stoke Therapeutics Trading Down 2.6%

Shares of NASDAQ STOK opened at $25.04 on Friday. The stock has a fifty day simple moving average of $27.99 and a two-hundred day simple moving average of $30.31. Stoke Therapeutics has a 1-year low of $20.32 and a 1-year high of $40.22. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -7.50 and a beta of 1.26.

Wall Street Analysts Forecast Growth

STOK has been the topic of several research reports. Guggenheim restated a "buy" rating and issued a $60.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Wedbush increased their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a research note on Friday, August 21st. They set an "overweight" rating and a $40.00 price target for the company. The Goldman Sachs Group reissued a "buy" rating on shares of Stoke Therapeutics in a report on Thursday, September 10th. Finally, Chardan Capital restated a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.25.

Insider Activity at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 2,861 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the transaction, the general counsel directly owned 21,225 shares of the company's stock, valued at approximately $679,836.75. This trade represents a 11.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Edward Kaye sold 12,567 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the transaction, the director directly owned 124,557 shares of the company's stock, valued at approximately $3,989,560.71. This trade represents a 9.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 34,594 shares of company stock worth $1,069,305. 9.60% of the stock is owned by corporate insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke's leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.